The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Open accessAbstract
BACKGROUND: Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and high mortality. We used the JAK inhibitor baricitinib, with IFN-blocking activity in vitro, to ameliorate disease. METHODS: Between October 2011 and February 2017, 10 patients with CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures), 4 patients with SAVI (stimulator of IFN genes-associated [STING-associated] vasculopathy with onset in infancy), and 4 patients with other interferonopathies were enrolled in an expanded access program. The patients underwent dose escalation, and the benefit was assessed by reductions in daily disease symptoms and corticosteroid requirement. Quality of life, organ inflammation, changes in IFN-induced biomarkers, and safety were longitudinally assessed. RESULTS: Eighteen patients were treated for a mean duration of 3.0 years (1.5-4.9 years). The median daily symptom score decreased from 1.3 (interquartile range [IQR], 0.93-1.78) to 0.25 (IQR, 0.1-0.63) (P < 0.0001). In 14 patients receiving corticosteroids at baseline, daily prednisone doses decreased from 0.44 mg/kg/day (IQR, 0.31-1.09) to 0.11 mg/kg/day (IQR, 0.02-0.24) (P < 0.01), and 5 of 10 patients with CANDLE achieved lasting clinical remission. The patients' quality of life and height and bone mineral density Z-scores significantly improved, and their IFN biomarkers decreased. Three patients, two of whom had genetically undefined conditions, discontinued treatment because of lack of efficacy, and one CANDLE patient discontinued treatment because of BK viremia and azotemia. The most common adverse events were upper respiratory infections, gastroenteritis, and BK viruria and viremia. CONCLUSION: Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interferonopathies. Monitoring safety and efficacy is important in benefit-risk assessment. TRIAL REGISTRATION: ClinicalTrials.gov NCT01724580 and NCT02974595. FUNDING: This research was supported by the Intramural Research Program of the NIH, NIAID, and NIAMS. Baricitinib was provided by Eli Lilly and Company, which is the sponsor of the expanded access program for this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Simple proton spectroscopic imaging.
Dixon, W. T. (1984) · Radiology · doi:10.1148/radiology.153.1.6089263 · Cited by 2,276
JAKS AND STATS: Biological Implications
Leonard, W. J., & O'Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,804
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
Self-citationIdentification of JAK2 as a growth hormone receptor-associated tyrosine kinase
Argetsinger, L. S., Campbell, G. S., Yang, X., Witthuhn, B. A., Silvennoinen, O., Ihle, J. N., & Carter-Su, C. (1993) · Cell · doi:10.1016/0092-8674(93)90415-m · Cited by 974
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., del Carmen Morales, L., Reyes Gonzaga, J., Yakushin, S., Ishii, T., Emoto, K., Beattie, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 872
Self-citationBaricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Self-citationJeremiah, N., Neven, B., Gentili, M., Callebaut, I., Maschalidi, S., Stolzenberg, M.-C., Goudin, N., Frémond, M.-L., Nitschke, P., Molina, T. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci79100 · Cited by 562
Gigantism in mice lacking suppressor of cytokine signalling-2
Metcalf, D., Greenhalgh, C. J., Viney, E., Willson, T. A., Starr, R., Nicola, N. A., Hilton, D. J., & Alexander, W. S. (2000) · Nature · doi:10.1038/35016611 · Cited by 491
Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 463
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., de Cassia Pellegrini, R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 695
Interferon target-gene expression and epigenomic signatures in health and disease
Barrat, F. J., Crow, M. K., & Ivashkiv, L. B. (2019) · Nature Immunology · doi:10.1038/s41590-019-0466-2 · Cited by 530
The type I interferonopathies: 10 years on
Crow, Y. J., & Stetson, D. B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00633-9 · Cited by 489
Metadata
- Authors
- Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., Stone, D. L., Gao, L., Klausmeier, T., Foell, D., de Jesus, A. A., Chapelle, D. C., Kim, H., Dill, S., Colbert, R. A., Failla, L., Kost, B., O’Brien, M., Reynolds, J. C., Folio, L. R., Calvo, K. R., Paul, S. M., Weir, N., Brofferio, A., Soldatos, A., Biancotto, A., Cowen, E. W., Digiovanna, J. J., Gadina, M., Lipton, A. J., Hadigan, C., Holland, S. M., Fontana, J., Alawad, A. S., Brown, R. J., Rother, K. I., Heller, T., Brooks, K. M., Kumar, P., Brooks, S. R., Waldman, M., Singh, H. K., Nickeleit, V., Silk, M., Prakash, A., Janes, J. M., Ozen, S., Wakim, P. G., Brogan, P. A., Macias, W. L., & Goldbach-Mansky, R.
- Venue
- Journal of Clinical Investigation
- Published
- 2018-06-11
- Volume
- 128
- Issue
- 7
- Pages
- 3041-3052
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2796581040
- Cited by
- 536
- References
- 38
- FWCI
- 23.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. https://app.cochat.ai/papers/10.1172/jci98814
- The paper
- Sanchez, G. A. M., Reinhardt, A., Ramsey, S., Wittkowski, H., Hashkes, P. J., Berkun, Y., Schalm, S., Murias, S., Dare, J. A., Brown, D., Stone, D. L., Gao, L., Klausmeier, T., Foell, D., de Jesus, A. A., Chapelle, D. C., Kim, H., Dill, S., Colbert, R. A., . . . Goldbach-Mansky, R. (2018). JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation. https://doi.org/10.1172/jci98814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.